Name | Conduritol B Epoxide |
Synonyms | CBE conduritolepoxide CONDURITOL C EPOXIDE Conduritol B Epoxide CONDURITOL B EPOXIDE 1,2-Anhydro-myo-inositol DL-1,2-ANHYDRO-MYO-INOSITOL |
CAS | 6090-95-5 |
Molecular Formula | C6H10O5 |
Molar Mass | 162.14 |
Density | 1.925±0.06 g/cm3 (20 ºC 760 Torr) |
Melting Point | 157-159 |
Boling Point | 360.5±42.0 °C(Predicted) |
Solubility | Soluble in Water (up to 25 mg/ml) or in DMSO |
Appearance | White solid |
Color | White |
pKa | 13.08±0.70(Predicted) |
Storage Condition | 2-8°C |
Stability | Moisture Sensitive |
In vitro study | Treating N2a and Conduritol B epoxide-N2a cells with G6 gave GC reductions to 7% and 26% of untreated levels, respectively. G6 treated Conduritol B epoxide-N2a also has significantly decreased GS. Co-treatment of G6 and dantrolene of Conduritol B epoxide-N2a cells lead to a similar degree of GC and GS reduction as G6 alone, indicating a specific effect of G6 on inhibition of substrate accumulation, Conduritol B epoxide-N2a cells have higher calcium levels than in N2a cells without caffeine at baseline. Conduritol B epoxide-N2a cells show a significant increase in cytosolic calcium levels compared to N2a cells. Conduritol B epoxide-N2a cells show a significant reduction in OCR as evidenced by approximately 50% in all the parameters, including rate of ATP production, basal respiration, and maximal respiration, compared to N2a cells, indicating reduced mitochondrial function in this nGD cell model. In dantrolene-treated Conduritol B epoxide-N2a cells, levels of Ryr3 are increased to 76% of WT level. |
In vivo study | Conduritol B epoxide treatment of 4L, 9H, 9V and WT mice (100 mg/kg/day, i.p.) from postnatal day 5 to 11 does not induce α-synuclein aggregates. Long-term daily Conduritol B epoxide treatment of 4L mice (100 mg/kg/day of Conduritol B epoxide from postnatal day 15 for 24 or 36 doses) leads to hind limb paralysis and small amounts of α-synuclein accumulation in the olfactory bulb, brainstem, and PVP near D3V (dorsal 3rd ventricle). |
WGK Germany | 3 |
Hazard Note | Harmful |
biological activity | Conduritol B epoxide is an irreversible, covalent β-glucosase inhibitor. |
in vitro study | Treating N2a and Conduritol B epoxide-N2a cells with G6 gave GC reductions to 7% and 26% of untreated levels, respectively. G6 treated Conduritol B epoxide-N2a also has significantly decreased GS. Co-treatment of G6 and dantrolene of Conduritol B epoxide-N2a cells lead to a similar degree of GC and GS reduction as G6 alone, indicating a specific effect of G6 on inhibition of substrate accumulation, conduritol B epoxide-N2a cells have higher calcium levels than in N2a cells without caffeine at baseline. Conduritol B epoxide-N2a cells show a significant increase in cytosolic calcium levels compared to N2a cells. Conduritol B epoxide-N2a cells show a significant reduction in OCR as evidenced by approximately 50% in all the parameters, including rate of ATP production, basic respiration, and maximal respiration, compared to N2a cells, indicating reduced mitochondrial function in this nGD cell model. in dantrolene-treated Conduritol B epoxide-N2a cells, levels of Ryr3 are increased to 76% of WT level. |
in vivo study | Conduritol B epoxide treatment of 4L, 9H, 9V and WT mice (100 mg/kg/day, I. p.) from postnatal day 5 to 11 does not induce alpha-synuclein aggregates. long-term daily Conduritol B epoxide treatment of 4l mice (100 mg/kg/day of Conduritol B epoxide from postnatal day 15 for 24 or 36 doses) led to hind limit paralysis and small amounts of alpha-synuclein accumulation in the olfactory bulb, brainstem, and PVP near D3V (dorsal 3rd ventricle). |